Decheng Capital
Latest statistics and disclosures from Decheng Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CGON, NUVB, PHAT, RCUS, KRYS, and represent 74.64% of Decheng Capital's stock portfolio.
- Added to shares of these 10 stocks: NUVB (+$44M), PHAT (+$7.2M), NAMS, LBPH, ACLX, KRYS, CGON, FDMT, MRUS, LEGN.
- Started 2 new stock positions in LBPH, RVMD.
- Reduced shares in these 2 stocks: ILMN, GRAL.
- Decheng Capital was a net buyer of stock by $59M.
- Decheng Capital has $422M in assets under management (AUM), dropping by 29.38%.
- Central Index Key (CIK): 0002010850
Tip: Access up to 7 years of quarterly data
Positions held by Decheng Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Decheng Capital
Decheng Capital holds 26 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cg Oncology (CGON) | 49.0 | $207M | 5.5M | 37.73 |
|
|
| Nuvation Bio (NUVB) | 14.1 | $59M | +273% | 26M | 2.29 |
|
| Phathom Pharmaceuticals (PHAT) | 5.4 | $23M | +47% | 1.3M | 18.08 |
|
| Arcus Biosciences Incorporated (RCUS) | 3.1 | $13M | 870k | 15.29 |
|
|
| Krystal Biotech (KRYS) | 3.1 | $13M | +9% | 72k | 182.03 |
|
| Illumina (ILMN) | 2.9 | $12M | -12% | 95k | 130.41 |
|
| Zentalis Pharmaceuticals (ZNTL) | 2.7 | $11M | 3.1M | 3.68 |
|
|
| BeyondSpring SHS (BYSI) | 2.7 | $11M | 5.0M | 2.29 |
|
|
| Newamsterdam Pharma Co Nv (NAMS) | 2.3 | $9.8M | +47% | 590k | 16.60 |
|
| Merus N V (MRUS) | 2.2 | $9.4M | +5% | 189k | 49.96 |
|
| Helix Acquisition Corp | 2.0 | $8.4M | 167k | 50.42 |
|
|
| Crinetics Pharmaceuticals In (CRNX) | 1.9 | $8.1M | 158k | 51.10 |
|
|
| Legend Biotech Corp- Adr (LEGN) | 1.3 | $5.3M | +10% | 109k | 48.73 |
|
| Cytokinetics (CYTK) | 1.2 | $5.0M | 94k | 52.80 |
|
|
| Aura Biosciences (AURA) | 1.1 | $4.6M | 516k | 8.91 |
|
|
| GeneDx Holdings Corp. Com Cl A (WGS) | 1.0 | $4.4M | 104k | 42.44 |
|
|
| 4d Molecular Therapeutics In (FDMT) | 1.0 | $4.3M | +14% | 398k | 10.81 |
|
| Equillium (EQ) | 0.9 | $3.7M | 4.4M | 0.83 |
|
|
| Vera Therapeutics (VERA) | 0.7 | $3.1M | 70k | 44.20 |
|
|
| Longboard Pharmaceuticals In (LBPH) | 0.4 | $1.9M | NEW | 56k | 33.33 |
|
| Arcellx (ACLX) | 0.4 | $1.8M | +1699% | 21k | 83.51 |
|
| Pyxis Oncology (PYXS) | 0.3 | $1.2M | 327k | 3.67 |
|
|
| AtriCure (ATRC) | 0.2 | $751k | 27k | 28.04 |
|
|
| Grail (GRAL) | 0.0 | $133k | -46% | 9.7k | 13.76 |
|
| Revolution Medicines (RVMD) | 0.0 | $91k | NEW | 2.0k | 45.35 |
|
| Nuvation Bio Warrants (NUVB.WS) | 0.0 | $63k | 646k | 0.10 |
|
Past Filings by Decheng Capital
SEC 13F filings are viewable for Decheng Capital going back to 2023
- Decheng Capital 2024 Q3 filed Nov. 15, 2024
- Decheng Capital 2024 Q2 filed Aug. 14, 2024
- Decheng Capital 2024 Q1 filed May 14, 2024
- Decheng Capital 2023 Q4 filed Feb. 12, 2024